http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#Head
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#provenance
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#pubinfo
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion
http://purl.obolibrary.org/obo/DOID_3393
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3393
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00315
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association
http://www.w3.org/2000/01/rdf-schema#label
"Zolmitriptan is contraindicated in patients with: Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or c Warnings and Precautions ( 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions ( 5.4 Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 Ischemic bowel disease [see Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks) [see Drug Interactions ( 7.2 Clinical Pharmacology ( 12.3 Known hypersensitivity to zolmitriptan (angioedema and anaphylaxis seen) [see Adverse Reactions ( 6.2 History of coronary artery disease (CAD) or coronary vasospasm ( 4 Symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 Monamine oxidase (MAO)-A inhibitor used in past 2 weeks ( 4 Known hypersensitivity to zolmitriptan ( 4"
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00315
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#provenance
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#pubinfo
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#sig
http://purl.org/nanopub/x/hasSignature
UFwMfnbaGsXMkKmJYORpF/4E3FM7g3KhP0yfjN0fKHKIV9GFuTXvLVRHgYEH1Yq0OYpIpgZjfYj0FkXU00esIvAETt0rGwEMQSbF10Tyn3wib73rmbaBBgmsn+KRJ3f6WReLN/Npt7VCmSII64VkrwrF7SUIXvHATMHo0rR4AlU=
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
http://purl.org/dc/terms/created
2021-08-23T18:00:23.548+02:00
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY